- Home
- COYA vs RPID Comparison
COYA vs RPID Comparison
Compare COYA & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- RPID
- Stock Information
- Founded
- COYA 2020
- RPID 2006
- Country
- COYA United States
- RPID United States
- Employees
- COYA N/A
- RPID N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- RPID Medical Specialities
- Sector
- COYA Health Care
- RPID Health Care
- Exchange
- COYA Nasdaq
- RPID Nasdaq
- Market Cap
- COYA 107.0M
- RPID 106.5M
- IPO Year
- COYA 2022
- RPID 2021
- Fundamental
- Price
- COYA $5.61
- RPID $3.21
- Analyst Decision
- COYA Strong Buy
- RPID Strong Buy
- Analyst Count
- COYA 4
- RPID 2
- Target Price
- COYA $16.50
- RPID $8.00
- AVG Volume (30 Days)
- COYA 116.6K
- RPID 70.7K
- Earning Date
- COYA 11-05-2025
- RPID 10-31-2025
- Dividend Yield
- COYA N/A
- RPID N/A
- EPS Growth
- COYA N/A
- RPID N/A
- EPS
- COYA N/A
- RPID N/A
- Revenue
- COYA $423,452.00
- RPID $30,289,000.00
- Revenue This Year
- COYA $40.80
- RPID $16.63
- Revenue Next Year
- COYA N/A
- RPID $21.98
- P/E Ratio
- COYA N/A
- RPID N/A
- Revenue Growth
- COYA N/A
- RPID 22.57
- 52 Week Low
- COYA $4.65
- RPID $0.83
- 52 Week High
- COYA $10.24
- RPID $4.50
- Technical
- Relative Strength Index (RSI)
- COYA 38.75
- RPID 59.14
- Support Level
- COYA $5.37
- RPID $2.93
- Resistance Level
- COYA $6.53
- RPID $3.52
- Average True Range (ATR)
- COYA 0.43
- RPID 0.23
- MACD
- COYA -0.12
- RPID 0.09
- Stochastic Oscillator
- COYA 15.89
- RPID 72.65
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.